Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Summary

This is a single arm, open-label, non-randomized and single-center phase II clinical study, to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib in patients with Radioactive Iodine-refractory Differentiated Thyroid Cancer (RAIR-DTC).

Timeline

Start

2020-09-23

Primary completion

2025-12-31

Completion

2025-12-31

Publications

• Zhang X, Sun D, Zhang Y, Mu Z, Shi C, Sun Y, Cheng X, Meng C, Wei X, Liang J, Lin Y. Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial. BMC Med. 2025 Dec 18;24(1):43. doi: 10.1186/s12916-025-04550-9.

Drugs

Indications